Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools.

Tolksdorf J, Kattan MW, Boorjian SA, Freedland SJ, Saba K, Poyet C, Guerrios L, De Hoedt A, Liss MA, Leach RJ, Hernandez J, Vertosick E, Vickers AJ, Ankerst DP.

BMC Med Res Methodol. 2019 Oct 15;19(1):191. doi: 10.1186/s12874-019-0839-0.

2.

A strategy for high-dimensional multivariable analysis classifies childhood asthma phenotypes from genetic, immunological, and environmental factors.

Krautenbacher N, Flach N, Böck A, Laubhahn K, Laimighofer M, Theis FJ, Ankerst DP, Fuchs C, Schaub B.

Allergy. 2019 Jul;74(7):1364-1373. doi: 10.1111/all.13745. Epub 2019 Mar 31.

3.

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.

Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ.

Eur Urol. 2018 Aug;74(2):197-203. doi: 10.1016/j.eururo.2018.05.003. Epub 2018 May 16.

4.

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Ankerst DP, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, Sanda MG, Gelfond J, Thompson IM, Leach RJ, Liss MA.

Eur Urol Focus. 2019 Jan;5(1):54-61. doi: 10.1016/j.euf.2018.01.010. Epub 2018 Feb 13.

5.

Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.

Thalgott M, Kron M, Brath JM, Ankerst DP, Thompson IM, Gschwend JE, Herkommer K.

World J Urol. 2018 Feb;36(2):177-185. doi: 10.1007/s00345-017-2122-5. Epub 2017 Nov 21.

PMID:
29164326
6.

Interactions between temperature and drought in global and regional crop yield variability during 1961-2014.

Matiu M, Ankerst DP, Menzel A.

PLoS One. 2017 May 26;12(5):e0178339. doi: 10.1371/journal.pone.0178339. eCollection 2017.

7.

Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: Results from prospective cohort data.

Beyerlein A, Strobl AN, Winkler C, Carpus M, Knopff A, Donnachie E, Ankerst DP, Ziegler AG.

Vaccine. 2017 Mar 27;35(14):1735-1741. doi: 10.1016/j.vaccine.2017.02.049. Epub 2017 Mar 3.

PMID:
28268073
8.

Novel Definitions of Low-risk and High-risk Prostate Cancer: Implications for the European Randomized Study of Screening for Prostate Cancer Risk Assessment Tool.

Pruthi DK, Ankerst DP, Liss MA.

Eur Urol. 2017 Jul;72(1):52-53. doi: 10.1016/j.eururo.2017.02.009. Epub 2017 Feb 17. No abstract available.

PMID:
28222931
9.

A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors.

Sadim M, Xu Y, Selig K, Paulus J, Uthe R, Agarwl S, Dubin I, Oikonomopoulou P, Zaichenko L, McCandlish SA, Van Horn L, Mantzoros C, Ankerst DP, Kaklamani VG.

Cancer. 2017 Jul 1;123(13):2413-2421. doi: 10.1002/cncr.30628. Epub 2017 Feb 14.

10.

Comparison of approaches for incorporating new information into existing risk prediction models.

Grill S, Ankerst DP, Gail MH, Chatterjee N, Pfeiffer RM.

Stat Med. 2017 Mar 30;36(7):1134-1156. doi: 10.1002/sim.7190. Epub 2016 Dec 11.

PMID:
27943382
11.

Improving prediction models with new markers: a comparison of updating strategies.

Nieboer D, Vergouwe Y, Ankerst DP, Roobol MJ, Steyerberg EW.

BMC Med Res Methodol. 2016 Sep 27;16(1):128.

12.

Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods.

Patel TA, Puppala M, Ogunti RO, Ensor JE, He T, Shewale JB, Ankerst DP, Kaklamani VG, Rodriguez AA, Wong ST, Chang JC.

Cancer. 2017 Jan 1;123(1):114-121. doi: 10.1002/cncr.30245. Epub 2016 Aug 29.

13.
14.

Perioperative transfusion of leukocyte depleted blood products in gastric cancer patients negatively influences oncologic outcome: A retrospective propensity score weighted analysis on 610 curatively resected gastric cancer patients.

Reim D, Strobl AN, Buchner C, Schirren R, Mueller W, Luppa P, Ankerst DP, Friess H, Novotny A.

Medicine (Baltimore). 2016 Jul;95(29):e4322. doi: 10.1097/MD.0000000000004322.

15.

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.

Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J.

Prostate. 2016 Sep;76(12):1120-9. doi: 10.1002/pros.23200. Epub 2016 May 16.

16.

Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.

Ankerst DP, Gelfond J, Goros M, Herrera J, Strobl A, Thompson IM Jr, Hernandez J, Leach RJ.

J Urol. 2016 Aug;196(2):355-60. doi: 10.1016/j.juro.2016.03.011. Epub 2016 Mar 12.

17.

The Role of Magnetic Resonance Imaging in Prostate Cancer: Focusing on What Really Matters.

Thompson IM Jr, Ankerst DP.

Eur Urol. 2016 Oct;70(4):574-575. doi: 10.1016/j.eururo.2016.01.039. Epub 2016 Feb 6. No abstract available.

PMID:
26861475
18.

A case control study of sarcosine as an early prostate cancer detection biomarker.

Ankerst DP, Liss M, Zapata D, Hoefler J, Thompson IM, Leach RJ.

BMC Urol. 2015 Oct 1;15:99. doi: 10.1186/s12894-015-0095-5.

19.

Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.

Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, Ankerst DP, Liss MA.

Eur Urol. 2016 Mar;69(3):407-10. doi: 10.1016/j.eururo.2015.08.029. Epub 2015 Aug 28.

PMID:
26320383
20.

No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.

Brath JM, Grill S, Ankerst DP, Thompson IM Jr, Gschwend JE, Herkommer K.

J Urol. 2016 Feb;195(2):343-8. doi: 10.1016/j.juro.2015.07.097. Epub 2015 Jul 31.

PMID:
26239337
21.

Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators.

Strobl AN, Vickers AJ, Van Calster B, Steyerberg E, Leach RJ, Thompson IM, Ankerst DP.

J Biomed Inform. 2015 Aug;56:87-93. doi: 10.1016/j.jbi.2015.05.001. Epub 2015 May 16.

22.

Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.

Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW.

Eur Urol. 2015 Dec;68(6):1083-8. doi: 10.1016/j.eururo.2015.03.023. Epub 2015 Mar 25.

23.

Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group.

Nieboer D, Vergouwe Y, Roobol MJ, Ankerst DP, Kattan MW, Vickers AJ, Steyerberg EW; Prostate Biopsy Collaborative Group.

J Clin Epidemiol. 2015 Apr;68(4):426-34. doi: 10.1016/j.jclinepi.2014.11.022. Epub 2014 Nov 29.

24.

Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening.

Gelfond J, Choate K, Ankerst DP, Hernandez J, Leach RJ, Thompson IM Jr.

J Urol. 2015 Jul;194(1):46-51. doi: 10.1016/j.juro.2015.02.043. Epub 2015 Feb 14.

PMID:
25686543
25.

A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation.

Grill S, Fallah M, Leach RJ, Thompson IM, Hemminki K, Ankerst DP.

J Clin Epidemiol. 2015 May;68(5):563-73. doi: 10.1016/j.jclinepi.2015.01.006. Epub 2015 Jan 14.

PMID:
25684153
26.
27.

Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator.

Grill S, Fallah M, Leach RJ, Thompson IM, Freedland S, Hemminki K, Ankerst DP.

J Urol. 2015 Feb;193(2):460-5. doi: 10.1016/j.juro.2014.09.018. Epub 2014 Sep 19.

28.

Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making.

Thompson IM Jr, Leach RJ, Ankerst DP.

JAMA. 2014 Sep 10;312(10):995-6. doi: 10.1001/jama.2014.9680. No abstract available.

29.

Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials.

Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Schulz C, Mansmann U, Heinemann V.

Acta Oncol. 2015 Feb;54(2):187-93. doi: 10.3109/0284186X.2014.938830. Epub 2014 Jul 14. Review.

PMID:
25017379
30.

Reply: To PMID 24862395.

Ankerst DP, Thompson IM.

Urology. 2014 Jun;83(6):1368. doi: 10.1016/j.urology.2014.02.037. No abstract available.

PMID:
24862397
31.

Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, Sokoll LJ, Sanda MG, Wei JT, Leach RJ, Thompson IM.

Urology. 2014 Jun;83(6):1362-7. doi: 10.1016/j.urology.2014.02.035.

32.

Chilling outweighs photoperiod in preventing precocious spring development.

Laube J, Sparks TH, Estrella N, Höfler J, Ankerst DP, Menzel A.

Glob Chang Biol. 2014 Jan;20(1):170-82. doi: 10.1111/gcb.12360. Epub 2013 Oct 30.

PMID:
24323535
33.

The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer.

Medina EA, Shi X, Grayson MH, Ankerst DP, Livi CB, Medina MV, Thompson IM Jr, Leach RJ.

Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):309-15. doi: 10.1158/1055-9965.EPI-13-0574. Epub 2013 Dec 2.

34.

Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score.

Ankerst DP, Till C, Boeck A, Goodman PJ, Tangen CM, Thompson IM.

Urology. 2013 Nov;82(5):1076-81. doi: 10.1016/j.urology.2013.07.041. Epub 2013 Sep 20.

35.

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome.

Vickers AJ, Sjoberg DD, Ankerst DP, Tangen CM, Goodman PJ, Thompson IM Jr.

Cancer. 2013 Aug 15;119(16):3007-11. doi: 10.1002/cncr.28114. Epub 2013 May 29.

36.

Nutrient status: a missing factor in phenological and pollen research?

Jochner S, Höfler J, Beck I, Göttlein A, Ankerst DP, Traidl-Hoffmann C, Menzel A.

J Exp Bot. 2013 Apr;64(7):2081-92. doi: 10.1093/jxb/ert061.

37.

Real-time individual predictions of prostate cancer recurrence using joint models.

Taylor JM, Park Y, Ankerst DP, Proust-Lima C, Williams S, Kestin L, Bae K, Pickles T, Sandler H.

Biometrics. 2013 Mar;69(1):206-13. doi: 10.1111/j.1541-0420.2012.01823.x. Epub 2013 Feb 4.

38.

The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.

Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J, Wei JT, Thompson IM.

J Urol. 2013 Jul;190(1):70-6. doi: 10.1016/j.juro.2012.12.108. Epub 2013 Jan 9.

39.

Prostate cancer incidence and survival in immigrants to Sweden.

Hemminki K, Ankerst DP, Sundquist J, Mousavi SM.

World J Urol. 2013 Dec;31(6):1483-8. doi: 10.1007/s00345-012-1021-z. Epub 2013 Jan 11.

PMID:
23306784
40.

Temporal changes in the clinical approach to diagnosing prostate cancer.

Hilton WM, Padalecki SS, Ankerst DP, Leach RJ, Thompson IM.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):162-8. doi: 10.1093/jncimonographs/lgs038.

41.

Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.

Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Mansmann U, Heinemann V.

Clin Cancer Res. 2013 Jan 1;19(1):225-35. doi: 10.1158/1078-0432.CCR-12-1515. Epub 2012 Nov 13.

42.

Words of wisdom. Re: Combining 33 genetic variants with prostate-specific antigen for the prediction of prostate cancer: longitudinal study.

Ankerst DP, Thompson IM.

Eur Urol. 2012 Jul;62(1):180. doi: 10.1016/j.eururo.2012.04.010. No abstract available.

PMID:
22640856
43.

The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting.

Liang Y, Ankerst DP, Feng Z, Fu R, Stanford JL, Thompson IM.

Urol Oncol. 2013 Nov;31(8):1464-9. doi: 10.1016/j.urolonc.2012.03.012. Epub 2012 May 1.

44.

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ, Thompson IM.

World J Urol. 2014 Feb;32(1):185-91. doi: 10.1007/s00345-012-0869-2. Epub 2012 Apr 22.

45.

Editorial for special issue on epidemiology and prevention of prostate cancer.

Thompson IM, Ankerst DP.

World J Urol. 2012 Apr;30(2):129-30. doi: 10.1007/s00345-012-0830-4. Epub 2012 Jan 22. No abstract available.

PMID:
22270263
46.

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Stephen Jones J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schröder FH, Lilja H, Vickers AJ.

World J Urol. 2012 Apr;30(2):181-7. doi: 10.1007/s00345-011-0818-5. Epub 2011 Dec 31.

47.

The benefits of risk assessment tools for prostate cancer.

Thompson IM, Ankerst DP.

Eur Urol. 2012 Apr;61(4):662-3. doi: 10.1016/j.eururo.2011.12.012. Epub 2011 Dec 20. No abstract available.

48.

Updating risk prediction tools: a case study in prostate cancer.

Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM.

Biom J. 2012 Jan;54(1):127-42. doi: 10.1002/bimj.201100062. Epub 2011 Nov 17.

49.

Association analysis of frost tolerance in rye using candidate genes and phenotypic data from controlled, semi-controlled, and field phenotyping platforms.

Li Y, Böck A, Haseneyer G, Korzun V, Wilde P, Schön CC, Ankerst DP, Bauer E.

BMC Plant Biol. 2011 Oct 27;11:146. doi: 10.1186/1471-2229-11-146.

50.

Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.

Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG.

Cancer. 2012 May 15;118(10):2651-8. doi: 10.1002/cncr.26396. Epub 2011 Oct 17.

Supplemental Content

Loading ...
Support Center